India, emerging markets power business of pharma majors amid US slowdown

An analysis of Q1 results show Sun Pharma and Aurobindo Pharma delivering strong growth, while Dr Reddy’s earnings were hit by lower lenalidomide sales and a semaglutide-related provision
Key takeaways
- Category: Results.
Why it matters
A routine update. Use the price and stock snapshot to gauge how the market is responding.


